The stock of China Cord Blood Corp (NYSE:CO) is a huge mover today! The stock increased 6.26% or $0.43 on April 6, reaching $7.3. About 501,183 shares traded or 372.63% up from the average. China Cord Blood Corp (NYSE:CO) has risen 30.61% since August 30, 2016 and is uptrending. It has outperformed by 22.48% the S&P500.The move comes after 7 months positive chart setup for the $574.02M company. It was reported on Apr, 6 by Barchart.com. We have $7.81 PT which if reached, will make NYSE:CO worth $40.18 million more.
Among 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Horizon Pharma had 24 analyst reports since September 9, 2015 according to SRatingsIntel. Mizuho maintained the stock with “Buy” rating in Monday, October 31 report. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Mkt Outperform” rating by JMP Securities on Wednesday, September 9. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Citigroup on Monday, November 28. Goldman Sachs initiated the shares of HZNP in report on Thursday, December 17 with “Buy” rating. The firm has “Hold” rating given on Tuesday, September 22 by Brean Capital. Mizuho initiated the shares of HZNP in report on Friday, October 9 with “Buy” rating. Mizuho maintained the stock with “Buy” rating in Tuesday, September 13 report. The rating was maintained by Mizuho on Tuesday, February 28 with “Buy”. The firm earned “Buy” rating on Tuesday, January 19 by Jefferies. Mizuho maintained the shares of HZNP in report on Tuesday, May 10 with “Buy” rating. See Horizon Pharma PLC (NASDAQ:HZNP) latest ratings:
28/02/2017 Broker: Mizuho Rating: Buy Old Target: $25 New Target: $22 Maintain
16/12/2016 Broker: Mizuho Old Rating: Neutral New Rating: Buy Old Target: $14 New Target: $25 Upgrade
09/12/2016 Broker: Mizuho Old Rating: Buy New Rating: Neutral Old Target: $30.00 New Target: $14.00 Downgrade
28/11/2016 Broker: Citigroup Old Rating: Neutral New Rating: Buy Upgrade
08/11/2016 Broker: Mizuho Rating: Buy Old Target: $29 New Target: $30 Maintain
31/10/2016 Broker: Mizuho Rating: Buy Old Target: $33 New Target: $29 Maintain
China Cord Blood Corporation is a provider of cord blood banking services in China. The company has market cap of $574.02 million. The Firm and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It has a 38.06 P/E ratio. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
Among 2 analysts covering China Cord Blood (NYSE:CO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. China Cord Blood had 4 analyst reports since August 21, 2015 according to SRatingsIntel. The firm earned “Sector Perform” rating on Friday, February 5 by Howard Weil. Roth Capital maintained China Cord Blood Corp (NYSE:CO) on Friday, August 28 with “Hold” rating. The company was maintained on Friday, August 21 by TH Capital.
Analysts await China Cord Blood Corp (NYSE:CO) to report earnings on June, 13.
Investors sentiment decreased to 0.69 in Q4 2016. Its down 0.08, from 0.77 in 2016Q3. It worsened, as 5 investors sold China Cord Blood Corp shares while 8 reduced holdings. 4 funds opened positions while 5 raised stakes. 6.47 million shares or 1.88% more from 6.35 million shares in 2016Q3 were reported. Fin Counselors stated it has 86,830 shares. State Street reported 28,720 shares stake. Rock Springs Capital Lp holds 880,000 shares or 0.36% of its portfolio. The Washington-based Parametric Portfolio Ltd Liability has invested 0% in China Cord Blood Corp (NYSE:CO). Wells Fargo And Commerce Mn has invested 0% in China Cord Blood Corp (NYSE:CO). Pnc Serv Group Incorporated reported 0% of its portfolio in China Cord Blood Corp (NYSE:CO). Gsa Cap Llp invested in 0.01% or 20,400 shares. California Pub Employees Retirement Sys stated it has 143,700 shares. Citigroup Inc holds 0% of its portfolio in China Cord Blood Corp (NYSE:CO) for 695,471 shares. 1.16 million were reported by Credit Suisse Ag. Commercial Bank Of America De holds 0% in China Cord Blood Corp (NYSE:CO) or 40,000 shares. State Bank Of Montreal Can invested in 1,000 shares. Peak6 Investments L P owns 225,000 shares. Glg Prtn Limited Partnership stated it has 0.39% of its portfolio in China Cord Blood Corp (NYSE:CO). Advisory owns 46,841 shares.
Horizon Pharma Public Limited Company is a biopharmaceutical company. The company has market cap of $2.34 billion. The Firm is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. It currently has negative earnings. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Since February 28, 2017, it had 0 insider buys, and 1 sale for $509,796 activity. The insider Carey Robert sold $509,796.
